Revance Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview

Revance Therapeutics

03/11/2023 11:16

* Revance Therapeutics Inc  RVNC.OQ   RVNC.O  is expected
to show
a rise in quarterly revenue when it reports  results 
    * The Nashville Tennessee-based  company is expected to
report  a
107.2% increase in revenue to $60.121 million from $29.02
million a year ago, according to the mean estimate from 11
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Revance
Therapeutics Inc
is for a loss of 89 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Revance
Therapeutics Inc is $35​, above​ its last closing price
of $8.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.79       -0.78      -0.80     Missed  -2.9
 Mar. 31 2023  -0.74       -0.70      -0.74     Missed  -5.9
 Dec. 31 2022  -1.05       -0.95      -0.95     Met     -0.1​
 Sep. 30 2022  -0.91       -0.89      -1.17     Missed  -30.8
 ​​Jun.        -0.89       -0.86      -0.88     Missed  -2.3
 30 2022                                                
 Mar. 31 2022  -0.93       -0.83      -0.94     Missed  -12.6​
 Dec. 31 2021  -0.95       -1.00      -0.93     Beat    6.6
 Sep. 30 2021  -1.15       -1.15      -1.10     Beat    4.5
 This summary was machine generated November 3 at 11:16 GMT.  All
figures in US dollars  unless otherwise stated